Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 13,937 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Dementia
Interventions: Otago Exercise Program; Other
Lead sponsor: Augusta University; Other
Eligibility: 55 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Depression, Unipolar
Interventions: Hatha Yoga Practice Group, Attention Control Education Group; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 14 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nonalcoholic Fatty Liver Disease, HIV
Interventions: Aramchol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • La Crosse, Wisconsin

Conditions: Muscular Dystrophy, Duchenne
Interventions: Oxatomide (tinset); Drug
Lead sponsor: Cooperative International Neuromuscular Research Group; Network
Eligibility: 5 Years to 10 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Pneumonia, Blood Stream Infection
Interventions: colistin and meropenem, colistin and placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 95 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Detroit, Michigan • Royal Oak, Michigan + 2 more

Conditions: DIEP Flap, Breast Reconstruction, Breast Cancer
Interventions: Use of ORASIS Device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Parkinson Disease
Interventions: Personal KinetiGraph® (PKG®) Watch, Personal KinetiGraph® (PKG®) Report; Device
Lead sponsor: Global Kinetics Corporation; Industry
Eligibility: 46 Years to 83 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 17
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Menlo Park, California + 14 more

Conditions: COVID-19
Interventions: hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline); Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Essential Tremor
Interventions: Perampanel, Placebo; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depressive Disorder
Interventions: Star*D algorithm, rEEG-guided therapy; Other
Lead sponsor: MYnd Analytics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 13
States / cities: Glendale, California • Irvine, California • San Bernardino, California + 10 more

Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions: Short course radiation, Active Surveillance; Radiation · Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Gastroparesis
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Morbid Obesity, Pregnancy
Interventions: Misoprostol; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure, Quality of Life
Interventions: Problem-Solving Treatment, Time Management; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Postoperative Delirium, Sleep, Anesthesia
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 469 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anomia, Aphasia, Traumatic Brain Injury, Cerebrovascular Accident
Interventions: Errorful training condition, Errorless training condition; Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cognitive Decline, Nutrition, Healthy, Brain Injuries
Interventions: Blueberry powder, Controlled and matched powder; Dietary Supplement · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years to 99 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Disease
Interventions: OC-02 (simpinicline) nasal spray, Placebo (vehicle) nasal spray; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Louisville, Kentucky • Nashville, Tennessee

Conditions: Hand Injuries, Trauma, Hand Injuries and Disorders
Interventions: Postoperative phone call; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pneumonia, Diabetes, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions: Social Incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Graves' Disease
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Glendale, Arizona • Los Angeles, California • San Jose, California + 11 more

Conditions: Restless Legs Syndrome, Iron Deficiency Anemia
Interventions: Ferumoxytol intravenous, Ferrous sulfate; Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

The Influence of the Otago Exercise Program on Executive Function Among People Living With Mild to Moderate Dementia

Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

ORASIS in Breast Reconstruction

Utilization of Target Ranges to Treat Parkinson's Disease With the PKG

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor

rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

Buspirone for Early Satiety and Symptoms of Gastroparesis

Induction of Labor in Morbidly Obese Patients

Improving Quality of Life in Heart Failure

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep

Cognitive Therapy to Improve Word Finding

Long-term Effects of Blueberry Supplementation on Brain Health in Older Adults

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

The Effects of Postoperative Physician Phone Calls for Hand and Wrist Fractures

Social Incentives to Increase Mobility

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)